MDCXW Medicus Pharma Ltd.

Price Chart

Executive Summary

Medicus Pharma entered into a $22M secured note financing with Streeterville Capital, with $12M received upfront and $10M held in a restricted deposit account at Lakeside Bank under a DACA. Simultaneously, the company disclosed receipt of a Nasdaq delisting determination notice, triggering an Event of Default under the notes and creating existential going-concern risk. The delisting risk and punitive loan terms (high prepayment premiums, trigger penalties, restrictive covenants) dominate the filing's impact.

Key Financial Metrics

Actionable Insight

Key Facts

• Streeterville Capital provided $22M in secured promissory notes: A-1 Note ($12,864,225 principal, 8.75% interest, 18-month maturity) and B Note ($10,000,000 principal, 5% interest, 18-month maturity). Net proceeds to company: $12M after $864K in fees/OID.
• The B Note ($10M) is cash-collateralized in a Lakeside Bank account under a DACA — it is effectively a restricted escrow, not free cash to the company.
• Item 3.01 discloses receipt of a Nasdaq delisting determination notice — this triggers an immediate Event of Default under Section 4.1(n) of the Notes, giving the lender the right to accelerate all ~$22.9M principal plus penalty fees.
• The A-1 Note carries a Trigger Effect allowing the lender to increase the balance by 15% per Major Trigger Event (up to 3 times) and 5% per Minor Trigger Event (up to 3 times), plus prepayment penalties of 110-115%.
• $2.5M of the proceeds were used at closing to repay an existing YA II PN debenture — indicating the company did not receive $22M of fresh capital.
• All subsidiaries (SkinJect, MPI, Antev, MDCX Holdings) provided full asset guarantees, including a lien on all of Antev's key teverelix-TFA patents.

Financial Impact

$22.9M total principal exposure on a ~$19M market cap company. Only $12M was received as unrestricted cash. The $10M B Note is locked in escrow and may only be released via A Note exchanges tied to repayment of the A-1 Note, creating a liquidity trap.

Risk Factors

• Nasdaq delisting would collapse liquidity and make the warrants (MDCXW) nearly worthless.
• Streeterville can trigger default and enforce liens on all subsidiary assets including the teverelix-TFA patent portfolio.
• Restrictive covenants block nearly all alternative financing including variable-rate deals and ATM issuances without Streeterville consent.
• Prepayment penalties (110-115%) make refinancing expensive. Trigger penalties (15% per Major Trigger Event) rapidly inflate the debt balance.

Market Snapshot

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

US Market Status

Related Tickers